MRK vs XOM: Which Is the Better Buy?

Side-by-side comparison of Merck & Co., Inc. and Exxon Mobil Corporation โ€” fair value, conviction, valuation metrics, and QuantHub research signals. Updated 2026-04-11.
Merck & Co., Inc. ยท Healthcare
$121.42
-2.9% upside to fair value
Med Conviction Grade B
VS
Exxon Mobil Corporation ยท Energy
$152.30
-33.0% upside to fair value
Med Conviction Grade C+
QuantHub Verdict
MRK has more upside to fair value (-2.9%). MRK trades at a lower forward P/E (14.0x). These are model outputs โ€” not personalized investment advice. See all research โ†’
Valuation & Fundamentals
Metric MRK XOM
Current Price $121.42 $152.30
Fair Value Estimate $118.00 $102.00
Upside to Fair Value -2.9% -33.0%
Market Cap $300.2B $634.6B
Forward P/E 14.0x 17.5x
EV / EBITDA 11.8x 9.8x
Price / Sales 4.1x 2.0x
Price / FCF 21.4x 26.9x
Revenue Growth YoY +1.3% -4.5%
Gross Margin 81.5% 21.7%
Operating Margin 41.2% 10.5%
Return on Equity 34.7% 11.1%
Dividend Yield 3.1% 2.65%
FCF Yield 4.7% 3.72%
Analyst Consensus Buy Buy
Investment Thesis
MRK โ€” Merck & Co., Inc.
Merck is a top-5 global pharmaceutical company generating $65B in annual revenue with 81.5% gross margins and 28% net margins. Keytruda, the world's best-selling drug at $31.7B (49% of pharma revenue), faces patent expiry in 2028. Merck is aggressively building replacements through M&A and pipeline launches: Winrevair ($1.4B year one), Capvaxive ($759M), and the $6.7B Terns acquisition for TERN-7โ€ฆ
XOM โ€” Exxon Mobil Corporation
Exxon Mobil is a world-class integrated energy supermajor with unmatched Permian Basin scale following the Pioneer Natural Resources acquisition, a high-margin Guyana growth engine, and disciplined capital allocation. However, the stock remains significantly overvalued relative to its own 5-year history on every key metric. At $152, XOM trades at roughly 22x trailing earnings, 1.96x sales, and 27โ€ฆ
Accumulation Zones
Metric MRK XOM
Zone Low $88.00 $77.00
Zone High $100.00 $92.00
In Buy Zone? No No
โ† MRK Research    XOM Research โ†’    All Research